padrão (JJ_JJ_NN)_(~NN)

#Sem nome próprio
1. Java: ([\\w-/]*_JJ[RS]?\\s[\\w-/]*_JJ[RS]?\\s[\\w-/]*_NN[S]?)(?:\\s[\\w-/]*_(?:[^N]..?|N[^N].?)|\\s\\._|\\s,_|\\s:_|\\s;_|$)
		 ([\\w-/]*_JJ[RS]?\\s[\\w-/]*_JJ[RS]?\\s[\\w-/]*_NN[S]?)\\s(?:\\._|,_|:_|;_|(?![\\w-/]*_NN.?)) - ER menor
	// Obs: Para cada sentença etiquetada, é necessário remover a barra invertida
	
2. Perl: ([\w-/\\]*_JJ[RS]?\s[\w-/]*_JJ[RS]?\s[\w-/]*_NN[S]?)(?:\s[\w-/]*_(?:[^N]..?|N[^N].?)|\s\._|\s,_|\s:_|\s;_|$)		 
		 ([\w-/\\]*_JJ[RS]?\s[\w-/]*_JJ[RS]?\s[\w-/]*_NN[S]?)\s(?:\._|,_|:_|;_|(?![\w-/]*_NN.?)) - ER menor
	// \w Casa letras, dígitos, ou '_'.
	// 1 e 2 são equivalentes
	// "\\" por causa do "moderate\/". 
	// Regra termina com ponto final, vírgula, ponto e vírgula, dois pontos ou $.	
	// Teve termo com nome próprio (NNP), falso positivo

Sentences Examples:

HU_NNP was_VBD interrupted_VBN definitely_RB for_IN 12_CD patients_NNS :_: 7_CD underwent_VBD allogeneic_JJ bone_NN marrow_NN transplantation_NN ,_, 1_CD failed_VBD to_TO respond_VB after_IN 2_CD years_NNS of_IN treatment_NN ,_, 1_CD with_IN HbSC_NNP because_IN of_IN a_DT total_JJ Hb_NNP level_NN higher_JJR than_IN 13_CD g\/dL_NNP ,_, 2_CD refused_VBD to_TO pursue_VB the_DT treatment_NN after_IN 1_CD and_CC 2_CD years_NNS ,_, and_CC 1_CD patient_JJ developed_JJ malignancy_NN ._. 

Despite_IN a_DT sustained_JJ increase_NN in_IN HbF_NNP level_NN and_CC an_DT increase_NN in_IN hydroxyurea_NN doses_NNS to_TO 30_CD mg\/kg_NN per_IN day_NN ,_, a_DT girl_NN aged_VBN 13_CD months_NNS at_IN inclusion_NN with_IN previous_JJ history_NN of_IN splenic_JJ sequestration_NN ,_, was_VBD hospitalized_VBN 20_CD times_NNS during_IN these_DT 2_CD years_NNS of_IN HU_NNP therapy_NN and_CC continued_VBD to_TO present_VB multiple_JJ vaso-occlusive_JJ crises_NNS and_CC dactylitis_NNS during_IN the_DT first_JJ year_NN of_IN HU_NNP ._. 

She_PRP died_VBD during_IN the_DT second_JJ year_NN of_IN therapy_NN from_IN acute_JJ severe_JJ anemia_NN during_IN an_DT episode_NN of_IN splenic_JJ sequestration_NN ._.

Acute_JJ promyelocytic_JJ leukemia_NN was_VBD diagnosed_VBN in_IN a_DT 21-year-old_JJ female_NN after_IN 8_CD years_NNS of_IN HU_NNP therapy_NN ._. 

As_IN a_DT whole_NN ,_, 34_CD patients_NNS were_VBD considered_VBN at_IN risk_NN of_IN primary_JJ stroke_NN on_IN the_DT basis_NN of_IN abnormal_JJ TCD_NNP ,_, and_CC 7_CD of_IN the_DT 21_CD explored_VBN by_IN MRI\/MRA_NNP had_VBD moderate\/severe_JJ arterial_JJ stenosis_NN ._. 

Of_IN interest_NN ,_, 4_CD of_IN the_DT children_NNS included_VBN in_IN the_DT registry_NN at_IN younger_JJR than_IN 2_CD years_NNS developed_VBD episodes_NNS of_IN severe_JJ acute_JJ anemia_NN ._. 

We_PRP did_VBD not_RB address_VB the_DT reversibility_NN of_IN chronic_JJ organ_NN damage_NN ;_: it_PRP is_VBZ unknown_JJ whether_IN the_DT inhibition_NN of_IN sickling_NN could_MD affect_VB such_JJ preexisting_JJ lesions_NNS ._. 

There_EX is_VBZ concern_NN that_IN long-term_JJ hydroxyurea_NN therapy_NN may_MD be_VB carcinogenic_JJ or_CC leukemogenic_JJ ,_, because_IN some_DT other_JJ antineoplastic_JJ agents_NNS have_VBP such_JJ effects_NNS ._. 

Hydroxyurea_NN treatment_NN significantly_RB reduced_VBD total_JJ leukocyte_JJ counts_NNS from_IN pretreatment_NN values_NNS ._.

The_DT percentage_NN of_IN annexin_JJ V-labeled_JJ platelets_NNS was_VBD reduced_VBN during_IN hydroxyurea_NN treatment_NN -LRB-_-LRB- Table_NNP 2_CD -RRB-_-RRB- in_IN all_DT but_CC two_CD patients_NNS -LRB-_-LRB- Figure_NNP 1B_NNP -RRB-_-RRB- ._. 

From_IN the_DT SC_NNP group_NN ,_, aside_RB from_IN the_DT 2_CD patients_NNS who_WP had_VBD stroke_NN in_IN the_DT immediate_JJ posttrial_JJ period_NN prior_RB to_TO choosing_NN treatment_NN ,_, 1_CD patient_NN who_WP refused_VBD transfusion_NN and_CC 2_CD who_WP started_VBD transfusion_NN during_IN the_DT posttrial_JJ follow-up_JJ developed_JJ stroke_NN ._. 

One_CD 18-year_JJ old_JJ patient_NN ,_, who_WP had_VBD received_VBN hydroxyurea_NN for_IN 11_CD months_NNS and_CC had_VBD only_RB a_DT slight_JJ reduction_NN in_IN the_DT frequency_NN of_IN painful_JJ episodes_NNS ,_, died_VBD suddenly_RB from_IN asystole_NN while_IN he_PRP was_VBD hospitalized_VBN for_IN a_DT painful_JJ crisis_NN ._

No_DT autopsy_NN was_VBD performed_VBN and_CC death_NN was_VBD attributed_VBN to_TO a_DT probable_JJ underlying_JJ SCD-related_JJ myocardiopathy_NN ._. 

In_IN one_CD child_NN ,_, already_RB reported_VBN ,_, a_DT diagnosis_NN of_IN acute_JJ lymphoblastic_JJ leukemia_NN with_IN evidence_NN of_IN Philadelphia_NNP chromosome_NN was_VBD made_VBN 1.5_CD months_NNS after_IN starting_VBG hydroxyurea_NN ._

When_WRB the_DT acute_JJ chest_NN syndrome_NN was_VBD diagnosed_VBN ,_, patients_NNS had_VBD hypoxia_NN ,_, decreasing_VBG hemoglobin_NN values_NNS ,_, and_CC progressive_JJ multilobar_JJ pneumonia_NN ._. 

Among_IN the_DT specific_JJ causes_NNS were_VBD pulmonary_JJ fat_JJ embolism_NN and_CC 27_CD different_JJ infectious_JJ pathogens_NNS ._. 

A_DT specific_JJ cause_NN -LRB-_-LRB- either_CC pulmonary_JJ fat_JJ embolism_NN or_CC an_DT infectious_JJ agent_NN -RRB-_-RRB- was_VBD identified_VBN in_IN 256_CD -LRB-_-LRB- 38_CD percent_NN -RRB-_-RRB- episodes_NNS ._. 